Loading clinical trials...
Loading clinical trials...
Glutamate Concentrations in the Brain Over the Course of a Migraine-like Attack
To investigate the glutaminergic system in the onset of migraine-like attacks.
Glyceryl trinitrate infusion (GTN) is used to provoke migraine-like attacks in female migraine without aura patients. Apart from migraine without aura patients healthy female controls are also included as a control group. Over the course of a single day these females (migraineurs and healthy controls) were scanned three times on fixed time slots: before GTN infusion (baseline), 90 minutes and 270 minutes after start of GTN infusion. Scans are acquired on a 7 tesla scanner (Philips, Cleveland, USA) on software release 3 using a 32 channel receive array using single-volume proton magnetic resonance spectroscopy (1H MRS) with a volume of interest in the visual cortex glutamate, in which glutamate, GABA and other metabolites will be assessed. The primary endpoint; glutamate level changes towards the pre-ictal and ictal state with other metabolite (e.g. glutamine and GABA) changes as secondary endpoints.
Age
18 - 50 years
Sex
FEMALE
Healthy Volunteers
Yes
Start Date
April 1, 2015
Primary Completion Date
April 1, 2016
Completion Date
April 1, 2016
Last Updated
January 7, 2020
39
ACTUAL participants
Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)
DRUG
Lead Sponsor
Leiden University Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04939922